TSPYL1 P62S

CI-VAR-00003383Explore in graph →NP_003300.1:p.Pro62SerNM_003309.3:c.184C>TCIViC 2180 rs3828743

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Prostate Neoplasm2
TSPYL1 P62S	Abiraterone	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID8947 Prostate cancer cell lines over-expressing TSPYL1 P62S had similar levels of cell proliferation as control cells normally expressing TSPYL1 wildtype when treated with abiraterone. Authors note that TS… (full text at CIViC) PMID 29027195 · Qin et al., 2018 · Open in CIViC	civic
TSPYL1 P62S	Abiraterone + PrednisoneCombination	Predictive	B	Does Not Support Sensitivity Response	4	submitted	EID5861 In a prospective clinical trial, 87 metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone acetate/prednisone (AA/P) showed that TSPYL1 R62S (NC_000006.11:g.11660081… (full text at CIViC) PMID 29027195 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.